Compounds > 1-hydroxy-3-amino-2-pyrrolidone
Page last updated: 2024-10-21

1-hydroxy-3-amino-2-pyrrolidone and Atherosclerotic Parkinsonism

1-hydroxy-3-amino-2-pyrrolidone has been researched along with Atherosclerotic Parkinsonism in 2 studies

1-hydroxy-3-amino-2-pyrrolidone: a CNS depressant; structure in first source

Research Excerpts

ExcerptRelevanceReference
"Treatments for Parkinson's disease based on replacement of lost dopamine have several problems."1.31Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat. ( Brotchie, JM; Nash, JE, 2002)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nash, JE1
Brotchie, JM1
Kanthasamy, AG1
Kanthasamy, A1
Matsumoto, RR1
Vu, TQ1
Truong, DD1

Other Studies

2 other studies available for 1-hydroxy-3-amino-2-pyrrolidone and Atherosclerotic Parkinsonism

ArticleYear
Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat.
    Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17, Issue:3

    Topics: Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Dopamine; Dose-Response Relationsh

2002
Neuroprotective effects of the strychnine-insensitive glycine site NMDA antagonist (R)-HA-966 in an experimental model of Parkinson's disease.
    Brain research, 1997, Jun-06, Volume: 759, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Dopamine; Dopamine A

1997